KOSDAQBiotech & Pharma072020

Choong Ang Vaccine Laboratory

₩8,900▼ 1.11%2026-11-18 close
Market Cap
₩82.4B
Turnover
₩100M
Volume
20K
Shares out.
9.3M
PER
13.6×
PBR
0.8×
EPS
₩663
Dividend Yield
2.22%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

Animal Vaccine Maker: Quarterly Earnings in Focus

Choong ANG Vaccine Laboratory's annual sales rose for three straight years through 2025, but quarterly sales have fallen for three consecutive quarters in 2026, and the third quarter of 2026 produced a net loss attributable to controlling shareholders.

  1. 1

    Annual revenue grew from KRW 39.3 billion in 2022 to KRW 49.1 billion in 2025, the largest year in the 2022 to 2025 span.

  2. 2

    Operating margin peaked at 16.7% in 2023, fell to 12.6% in 2024 and recovered to 13.2% in 2025; the company's 2026 to 2028 target is 13% or higher.

  3. 3

    The third quarter of 2026 swung to a net loss attributable to controlling shareholders of KRW 146 million, while net income attributable to controlling shareholders over the last four quarters totals KRW 6.14 billion.

  4. 4

    The debt ratio stood at 16.6% at the end of 2025, and all KRW 105.4 billion of total equity belongs to controlling shareholders.

  5. 5

    The African swine fever (ASF) vaccine has largely completed R&D, national licensing is under way, and press reports say the company targets commercialization in 2027.

02

Business structure

Choong ANG Vaccine Laboratory is an animal vaccine company founded in 1968 that focuses on researching, manufacturing and selling veterinary vaccines.

Past press reports describe a product line of roughly 70 items, including the swine vaccine Suishot, the poultry vaccine Poulshot and companion-animal vaccines Caninshot and Felishot. Swine vaccines are the core of sales, and press reports say swine vaccine revenue has trended upward over the past decade.

Poultry and companion-animal vaccines form the other main product groups. Exports are a growing share: in a June 2026 interview the CEO said about 40% of total sales come from overseas, centered on the Middle East, Egypt and Latin America.

Customers are mainly government disease-control programs and livestock farms and distributors at home and abroad. A foot-and-mouth disease vaccine supply contract disclosed on July 8, 2026 was worth roughly KRW 5.8 billion and ran until November 7, 2026.

Past press reports described the company as the top animal vaccine maker in Korea and said it spends about 10% of annual sales on R&D. Its markets differ from those of human vaccine makers such as SK Bioscience, so direct comparisons are limited.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩11B₩1.5B14.1%
2025Q4₩12.8B₩1.1B8.9%
2026Q1₩12.6B₩3B23.8%
2026Q2₩11.9B₩1.1B9.6%
2026Q3₩11.5B₩1.6B13.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩39.3B₩4.3B₩4B10.9%4.2%20.5%
2023₩41.9B₩7B₩6B16.7%6.0%19.8%
2024₩45.6B₩5.8B₩6.9B12.6%6.6%18.7%
2025₩49.1B₩6.5B₩6.2B13.2%5.8%16.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 39.3 billion in 2022 to KRW 41.9 billion in 2023 (up 6.5% year on year), KRW 45.6 billion in 2024 (up 8.9%) and KRW 49.1 billion in 2025 (up 7.6%), increasing for three consecutive years from 2023 through 2025.

Operating profit went from KRW 4.28 billion in 2022 to KRW 6.99 billion in 2023, up 63.3%, making 2023 the largest year in the 2022 to 2025 span. It then fell to KRW 5.76 billion in 2024 (down 17.7%) and recovered to KRW 6.48 billion in 2025 (up 12.5%).

Operating margin moved from 10.9% in 2022 to 16.7% in 2023, then to 12.6% in 2024 and 13.2% in 2025.

Net income attributable to controlling shareholders rose from KRW 4.04 billion in 2022 to KRW 6 billion in 2023 (up 48.3%) and KRW 6.85 billion in 2024 (up 14.2%), making 2024 the largest year, before declining 10.1% to KRW 6.16 billion in 2025.

Net income including non-controlling interests is a separate line, and the company's filings show the same amounts for both in each year. Operating cash flow fell to KRW 7.87 billion in 2025 from KRW 13.4 billion in 2024, a decline steeper than the roughly 10% drop in net income.

The debt ratio declined from 20.5% in 2022 to 16.6% in 2025, pointing to a steadier balance sheet.

Quarterly revenue peaked at KRW 12.8 billion in the fourth quarter of 2025, then fell to KRW 12.6 billion in the first quarter of 2026, KRW 11.9 billion in the second and KRW 11.5 billion in the third, three consecutive quarterly declines.

Operating profit reached KRW 3 billion in the first quarter of 2026, up 161.9% from the prior quarter, then dropped to KRW 1.14 billion in the second quarter (down 61.8%) and rose to KRW 1.59 billion in the third (up 39.3%); the disclosed figures alone do not identify the cause of the first-quarter jump.

Third-quarter operating profit rose 2.9% year on year, yet the company swung to a net loss attributable to controlling shareholders of KRW 146 million. A higher operating profit alongside a net loss points to a burden below the operating line, such as non-operating items or taxes.

Net income attributable to controlling shareholders over the last four quarters totals KRW 6.14 billion, close to the KRW 6.16 billion posted for full-year 2025.

05

Industry analysis

Domestic analyses say tighter limits on antibiotic use have raised awareness of disease prevention, and demand for animal vaccines is growing steadily as a result.

A 2019 securities technical report noted that Korean animal drug exports grew by nearly 70% in 2018 from the prior year, showing that exports are one pillar of market growth.

Press reports say African swine fever (ASF) vaccines developed by two domestic companies received export product licenses, and field trials are under way in Vietnam and the Philippines.

Reports also say the government will open a BL3 facility needed for ASF vaccine production to private companies, and plans an additional private-use BL3 facility by 2030.

Reports note that China has also achieved results in recombinant-strain vaccine development following its genotype 2 vaccine, which has become a global policy challenge.

In foot-and-mouth disease vaccines, domestic development is advancing: a press report says the company and a partner received approval from the national quarantine authority for a clinical trial plan for a Korean-developed foot-and-mouth disease vaccine.

Past press reports describe the company as the top animal vaccine maker in Korea, but reliable head-to-head comparisons with rival firms are limited. Because livestock disease outbreaks and export regulations drive demand, the industry can swing with disease conditions and policy.

06

Outlook

In a value-up plan disclosed on March 25, 2026, the company set targets of average annual revenue growth of 5% or more and an operating margin of 13% or more for 2026 to 2028.

The same plan set a target of a price-to-book ratio of 1.2 times or higher in 2027 and a policy of raising total dividend payments by 10% or more each year from 2026 to 2028. The company also said it plans to cancel all of its treasury shares.

In a June 2026 interview, the CEO said the company aims to exceed KRW 50 billion in annual revenue for the first time since its founding.

That target is based on the existing business, and the company describes the ASF vaccine, the foot-and-mouth disease vaccine CDMO and the Egypt joint venture as separate additional factors.

However, disclosed revenue for the first three quarters of 2026 totals KRW 36 billion, so reaching KRW 50 billion would require fourth-quarter 2026 revenue of about KRW 14 billion, above the KRW 12.8 billion peak in the fourth quarter of 2025.

The ASF vaccine has largely completed R&D, national registration procedures are under way, and the company is considering direct sales as well as licensing to global animal health companies.

The joint venture with an Egyptian partner targets completion of a poultry vaccine plant and start of production this year, with the company saying royalty and other earnings contributions could begin in 2027 if the schedule holds. The foot-and-mouth disease vaccine CDMO business is also moving into full operation.

The next points to check are whether the Egypt plant is completed by the end of 2026, the progress of ASF vaccine licensing and commercialization in 2027, and delivery of the 2026 to 2028 dividend growth plan.

07

Valuation

PER
13.6×
PBR
0.8×
ROE
5.8%
EPS
₩663
BPS
₩11,497
Dividend per share
₩200

Valuation is usually viewed through earnings-based and book-value-based measures.

On earnings, the last four quarters total KRW 6.14 billion in net income attributable to controlling shareholders, but that window includes the third-quarter 2026 net loss, so multiples can look very different depending on which quarters are included.

On book value, the price-to-book ratio has moved below 1 times at each quarter-end since 2025. The company's 2027 target of 1.2 times or higher sits above that range. Whether the target is reached depends on how the share price and the equity base move together.

On dividends, compiled data show the dividend yield running above the average for the KOSDAQ pharmaceutical sector. The annual general meeting in March 2026 approved a cash dividend, and the company plans to raise total dividend payments by 10% or more each year from 2026 to 2028.

Operating margin is the more suitable profitability gauge here, and the 13.2% margin in 2025 is close to the company's 13% target for 2026 to 2028.

With total equity of KRW 105.4 billion and total liabilities of KRW 17.4 billion, financial capacity is substantial, and changes in share count from treasury share cancellation should be read alongside per-share measures.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Plan to expand overseas sales share

In a June 2026 interview, the CEO said about 40% of total sales come from exports and set a medium-term target of 60%. Expansion in the Middle East, Egypt and Latin America is the core of this effort. A larger overseas share could spread exposure away from domestic disease-control policy changes.

ASF vaccine and licensing options

The company says ASF vaccine R&D is essentially complete and national registration is under way. Besides direct sales, it is considering licensing out to global animal health companies. If approvals and deals materialize, they would form a new revenue source separate from existing vaccine sales.

Expanded shareholder return policy

The March 2026 value-up plan includes a policy of raising total dividend payments by 10% or more each year for 2026 to 2028. A plan to cancel treasury shares was presented alongside it. The 13.2% operating margin in 2025 is at the level of the company's 13% target, which offers a reference point for assessing the goal.

09

Bear factors

Three straight quarterly revenue declines

Revenue fell from KRW 12.8 billion in the fourth quarter of 2025, the peak, to KRW 12.6 billion in the first quarter of 2026, KRW 11.9 billion in the second and KRW 11.5 billion in the third. Third-quarter revenue rose 4.8% year on year but declined from the prior quarter. The gap between annual growth and quarterly trend is the main weakness in the recent figures.

Third-quarter net loss and slower cash flow

Net income attributable to controlling shareholders swung to a loss of KRW 146 million in the third quarter of 2026. Operating cash flow fell to KRW 7.87 billion in 2025 from KRW 13.4 billion in 2024. The cash decline was steeper than the profit decline, making cash generation a point to monitor.

Fourth-quarter revenue needed for the target

Reaching KRW 50 billion in annual revenue would require about KRW 14 billion in fourth-quarter 2026 revenue, above the KRW 12.8 billion peak of the fourth quarter of 2025. The ASF vaccine's commercialization target is 2027, and it remains before final approval. Until new businesses show results, the quarterly trend of the existing business will drive earnings.

10

Risk factors

Policy and procurement dependence

Government procurement contracts for vaccines such as foot-and-mouth disease vaccine depend on contract terms and delivery requests. The company itself noted in its disclosure that performance may change with the counterparty's delivery requirements.

The contract signed on July 8, 2026 ended on November 7, 2026, and any follow-on contract would appear in disclosures.

New business execution

Delays in ASF vaccine licensing, failure to close overseas licensing deals, or a delayed Egypt joint venture plant could push back the timing of earnings contributions. None of these new businesses are yet reflected in the disclosed results. The company itself treats them as separate factors outside its 2026 revenue target.

Quarterly earnings volatility

Operating profit swung from KRW 3 billion in the first quarter of 2026 to KRW 1.14 billion in the second, a wide range. As in the third quarter, operating profit can rise while the company still posts a net loss because of non-operating items and taxes. A single quarter is a weak basis for judging full-year earnings.

11

What to watch next

  1. End of December 2026

    Whether the Egypt joint venture completes its poultry vaccine plant and starts production as targeted. A delay would also push back the timing of royalty contributions expected from 2027.

  2. Early 2027

    Release of preliminary fourth-quarter 2026 operating results. This is the first point to gauge whether the KRW 50 billion annual revenue target is achievable, which would require fourth-quarter revenue of about KRW 14 billion.

  3. By end of March 2027

    Filing of the 2026 annual report and the dividend resolution at the annual general meeting. This is where the 13% operating margin target and the 10% dividend growth policy for 2026 can be checked against actual results.

  4. During 2027

    Country-by-country ASF vaccine approvals, commercialization progress and any global licensing agreement. These indicate when new businesses may begin to appear in reported results.

  5. End of December 2027

    The checkpoint for the 2027 target of a price-to-book ratio of 1.2 times or higher. Whether it is met depends on how the equity base and share price move together.

12

Overall view

Choong ANG Vaccine Laboratory is an animal vaccine company whose annual sales rose for three consecutive years from 2023 through 2025, with a 13.2% operating margin in 2025.

Quarterly revenue has fallen for three straight quarters in 2026, and the third quarter swung to a net loss attributable to controlling shareholders of KRW 146 million. Net income attributable to controlling shareholders over the last four quarters totals KRW 6.14 billion.

The company's targets are average annual revenue growth of 5% or more, an operating margin of 13% or more, a 2027 price-to-book ratio of 1.2 times or higher, and total dividend growth of 10% or more each year.

The ASF vaccine's licensing and commercialization, licensing deals and the Egypt joint venture plant are not yet reflected in disclosed results.

Positive factors include the planned rise in export share and the shareholder return policy, while negatives include the quarterly revenue decline and the fourth-quarter revenue level the KRW 50 billion target requires.

The next points to check are preliminary fourth-quarter 2026 operating results, the 2026 annual report and progress on ASF vaccine licensing.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. vegannews.co.kr
  3. news.nate.com
  4. m.news.nate.com
  5. ssl.pstatic.net
  6. butler.works
  7. dailyvet.co.kr
  8. topstarnews.net
  9. news.nate.com
  10. etoday.co.kr
  11. edaily.co.kr
  12. edaily.co.kr
  13. edaily.co.kr
  14. edaily.co.kr
  15. edaily.co.kr
  16. etoday.co.kr
  17. news.nate.com
  18. etoday.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis